Melqart Asset Management (Uk) LTD Vertex Pharmaceuticals Inc Transaction History

Melqart Asset Management (Uk) LTD

$1.18 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $33.2 Million - $39.1 Million	-150,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$177.01 - $223.45 $1.77 Million - $2.23 Million	10,000 Added 7.14%	150,000 $32.9 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $25.1 Million - $28 Million	-138,130 Reduced 49.66%	140,000 $25.4 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $1.64 Million - $1.93 Million	8,730 Added 3.24%	278,130 $56.1 Million
Q1 2021 May 17, 2021	BUY	$207.02 - $241.31 $26.5 Million - $30.9 Million	128,100 Added 90.66%	269,400 $57.9 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $9.9 Million - $13.2 Million	47,800 Added 51.12%	141,300 $33.4 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $3.96 Million - $4.7 Million	15,500 Added 19.87%	93,500 $25.4 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $450,960 - $591,600	-2,000 Reduced 2.5%	78,000 $22.6 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $41.5 Million - $51.5 Million	-207,900 Reduced 72.21%	80,000 $19 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $21.3 Million - $28.6 Million	127,900 Added 79.94%	287,900 $63 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $2.66 Million - $2.99 Million	16,000 Added 11.11%	160,000 $27.1 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $1.89 Million - $2.19 Million	11,500 Added 8.68%	144,000 $26.4 Million
Q1 2019 May 15, 2019	SELL	$163.73 - $194.7 $3.68 Million - $4.38 Million	-22,500 Reduced 14.52%	132,500 $24.4 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $23.5 Million - $29.8 Million	155,000 New	155,000 $25.7 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $31 Million - $35.6 Million	-184,800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $26.9 Million - $31.4 Million	184,800 New	184,800 $31.4 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

Capital World Investors Los Angeles, CA

26.7M
Shares

$13.4 Billion
2.1% of portfolio
Vanguard Group Inc Valley Forge, PA

23M
Shares

$11.5 Billion
0.21% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$10.7 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.7M
Shares

$5.89 Billion
0.24% of portfolio
Capital Research Global Investors Los Angeles, CA

8.54M
Shares

$4.29 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Melqart Asset Management (Uk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Melqart Asset Management (Uk) LTD with notifications on news.

Account